Mark Treherne is a Director and the Chairman of Talisman Therapeutics. He is responsible for the business strategy of Talisman. Mark has over 25 years’ experience in the discovery of novel treatments for diseases of the central and peripheral nervous systems, including Parkinson’s and Alzheimer’s diseases. Mark formerly worked with Pfizer where he was responsible for research into neurodegenerative diseases, including using stem-cell derived lines for screening compounds. In 1997, Mark set up Cambridge Drug Discovery as Chief Executive, which he sold to BioFocus in 2001. Mark has worked with many early-stage biotechnology companies, including CDD, Xention, Ampika, Population Genetics Technologies, Domain Therapeutics, Cyclofluidic and NeuroSolutions. Mark was formerly Chairman of ERBI for 3 years, which represents the biotechnology companies in the East of England (now One Nucleus). He was also Chief Executive of the Life Sciences Organisation of UK Trade & Investment and helped define the national investment strategy for dementia research in the UK. Mark is an author of over 70 articles published in the scientific and trade press. Mark obtained his PhD in receptor neuropharmacology from Cambridge University.